UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
DMRA holding history
Damora Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
DMRA overviewAll 13F holders of DMRAFull Q2 2026 holdings
- Shares (Q2 2026)
- 840,292
- Value
- $21.9M
- % of portfolio
- <0.1%
- Quarters held
- 15
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 840,292 | $21.9M | <0.1% | +679,877+423.8% | Added | Holders |
| Q1 2026 | 160,415 | $4.15M | <0.1% | +154,026+2,410.8% | Added | Holders |
| Q4 2025 | 6,389 | $147.0K | <0.1% | +6,330+10,728.8% | Added | Holders |
| Q3 2025 | 59 | $220 | <0.1% | −2,254−97.4% | Reduced | Holders |
| Q2 2025 | 2,313 | $7.89K | <0.1% | +2,028+711.6% | Added | Holders |
| Q1 2025 | 285 | $883 | <0.1% | −12,182−97.7% | Reduced | Holders |
| Q4 2024 | 12,467 | $58.0K | <0.1% | +7,368+144.5% | Added | Holders |
| Q3 2024 | 5,099 | $62.0K | <0.1% | +5,099 | New | Holders |
| Q1 2024 | 0 | $0 | 0.0% | −4,280−100.0% | Sold out | Holders |
| Q4 2023 | 4,280 | $3.08K | <0.1% | −2,808−39.6% | Reduced | Holders |
| Q3 2023 | 7,088 | $5.10K | <0.1% | +7,088 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −2,484−100.0% | Sold out | Holders |
| Q1 2023 | 2,484 | $4.94K | <0.1% | +2,484 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −4,097−100.0% | Sold out | Holders |
| Q3 2022 | 4,097 | $8.00K | <0.1% | +4,097 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −2,495−100.0% | Sold out | Holders |
| Q1 2022 | 2,495 | $5.00K | <0.1% | −4,248−63.0% | Reduced | Holders |
| Q4 2021 | 6,743 | $20.0K | <0.1% | +6,743 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −7,822−100.0% | Sold out | Holders |
| Q2 2021 | 7,822 | $40.0K | <0.1% | +7,822 | New | Holders |